Amarin (NASDAQ:AMRN) Stock Rating Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Amarin (NASDAQ:AMRN – Free Report) from a hold rating to a buy rating in a research note published on Monday,Wall Street Zen reports.

A number of other brokerages also recently commented on AMRN. Zacks Research downgraded Amarin from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. JPMorgan Chase & Co. started coverage on Amarin in a research report on Friday, August 21st. They set an “underweight” rating and a $13.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research note on Thursday, October 15th. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Amarin has a consensus rating of “Sell” and a consensus price target of $13.00.

View Our Latest Stock Report on Amarin

Amarin Price Performance

Shares of NASDAQ AMRN opened at $11.31 on Monday. The company has a market cap of $238.30 million, a PE ratio of -11.78 and a beta of 0.81. Amarin has a 12 month low of $11.25 and a 12 month high of $17.31. The company has a 50-day simple moving average of $12.49 and a 200-day simple moving average of $14.12.

Amarin (NASDAQ:AMRN – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Amarin had a negative net margin of 10.87% and a negative return on equity of 0.52%. The business had revenue of $39.55 million during the quarter, compared to analyst estimates of $43.76 million. On average, analysts anticipate that Amarin will post -0.85 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Brooklands Fund Management Ltd raised its holdings in shares of Amarin by 23.1% during the 3rd quarter. Brooklands Fund Management Ltd now owns 218,373 shares of the biopharmaceutical company’s stock valued at $2,839,000 after buying an additional 41,048 shares during the period. LCM Capital Management Inc grew its position in Amarin by 17.1% in the third quarter. LCM Capital Management Inc now owns 60,162 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 8,800 shares in the last quarter. R Squared Ltd grew its position in Amarin by 190.9% in the third quarter. R Squared Ltd now owns 49,272 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 32,334 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Amarin during the first quarter valued at approximately $278,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Amarin by 28.8% during the third quarter. Steward Partners Investment Advisory LLC now owns 11,479 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 2,569 shares during the period. Institutional investors and hedge funds own 22.25% of the company’s stock.

Amarin Company Profile

(Get Free Report)

Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative. In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia.

See Also

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.